GPX4 and nasopharyngeal carcinoma: We also revealed that GPX4 knockdown or low-dose treatment with GPX4-targeting inhibitors effectively reduces the chemoresistance of EBV-positive NPC cells, providing a potential therapeutic target for the treatment of chemoresistant tumors.